Orphan drug developers are navigating a more complex landscape.
FDA decision making has proved unpredictable, and rare disease programs must compete for attention as investment flows toward obesity and other large disease areas.
Even so, the underlying outlook for orphan drugs remains strong, supported by robust sales growth and recent policy wins.
This infographic brings together the key numbers and rankings shaping the orphan drug market in 2026 and beyond. From top selling therapies and companies to pipeline value and evolving US policy, it offers a clear, data led view of the market for orphan drugs out to 2032.
Download the infographic to discover:
- Why orphan drugs are forecast to account for over 21% of global prescription drug sales by 2032
- The top selling orphan drugs worldwide
- Which companies dominate orphan drug revenues today and who is closing the gap
- The most valuable orphan assets in the pipeline, ranked by forecast NPV
- How recent tweaks to the Inflation Reduction Act are reshaping incentives for multi indication orphan drugs
- Where regulatory and policy cross currents could still disrupt rare disease development
Access the report for a clear, data driven view of where value is building, where risk is rising, and what that means for rare disease portfolios.
